Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atrial Fibrillation
First patient dosed in phase III atrial arrhythmia studies
September 1st, 2003
Cardiome Pharma Corp. announced that it has commenced patient dosing in its initial phase III efficacy study of RSD1235 for the acute treatment of atrial fibrillation. The initial study, called ACT 1 (Atrial fibrillation Conversion Trial 1), will measure the safety and efficacy of RSD1235 in 420 patients. The placebo-controlled study is being carried out in 45 centers in the U.S., Canada, and Scandinavia. ACT 1 is the first of an expected three phase III studies required for FDA approval of RSD1235. Atrial fibrillation is an abnormal heart rhythm that affects the atria of the heart, lowering the heart's pumping capacity, and increasing the risk of...
Source: Health & Medicine Week (2003-09-01)
|
